SavedAdd your journal

Journals / İstanbul Üniversitesi İstanbul Tıp Fakültesi Mecmuası / 2002 / Cilt: 65 - Sayı: 4

Felty's syndrome: Sucesful remission induction and meintenance therapy with granulocyte macrophage colony stimulating factor

Felty sendromu: Granülosit makrofaj koloni uyarıcı faktör tedavisiyle başarılı remisyon indüksiyonu ve sürdürme tedavisi

Ahmet GÜL
Sevil KAMALI
Esen KASAPOĞLU
Yonca ÇAĞATAY
Aras Şenay MUTLU
Lale ÖCAL
Meral KONİÇE
Murat İNANÇ
Pages
279–282
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

G-CSF treatment seems to be an effective and safe option for both remission induction and maintenance therapy in FS.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Felty's syndrome (FS) is a clinical picture characterized with splenomegaly, leucopenia and recurrent infections in patients with rheumatoid arthritis (RA).
📊
Key Findings & Data:Cyclic G-CSF treatment was started as 30 MÜ/d at three times weekly and after the improvement of leucocyte count, splenectomy was performed.
💡
Conclusion & Impact:G-CSF treatment seems to be an effective and safe option for both remission induction and maintenance therapy in FS.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Felty's syndrome (FS) is a clinical picture characterized with splenomegaly, leucopenia and recurrent infections in patients with rheumatoid arthritis (RA). FS was accepted as a rare and potentially fatal extraarticular manifestation of RA. Herein, we presented a patient with FS who was admitted with splenomegaly, leucopenia and septicemia in addition to chronic polyarthritis. Although the articular symptoms were controlled by antibiotherapy and high dose corticosteroid treatment, leucopenia sustained. High dose corticosteroids, hydroxychloroquin, methotrexate and cyclosporin-A were tried during the follow-up which were succesfull in treating articular symptoms, but not leucopenia. Cyclic G-CSF treatment was started as 30 MÜ/d at three times weekly and after the improvement of leucocyte count, splenectomy was performed. Leucocyte count was not returned to normal levels after splenectomy and cyclic G-CSF treatment was restarted. The patient has been still in re-mission for 8 months with G-CSF treatment. G-CSF treatment seems to be an effective and safe option for both remission induction and maintenance therapy in FS.

Özet

Felty sendromu (FS), romatoid artritli (RA) hastalarda görülebilen ve splenomegali, lökopeni ve tekrarlayan infeksiyon bulgularıyla seyreden bir klinik tablodur. Burada, kronik poliartrit ile birlikte, splenomegali, lökopeni ve sepsis tablosuyla başvuran FS'li bir hasta sunuldu. Hastalığın başlangıcında antibiyoterapi ve granülosit koloni uyarıcı faktör (G-CSF) tedavisi ile lökopeni ve sepsis tablosu kontrol altına alınabildi. Ancak, takibi süresince farklı zamanlarda uygulanan yüksek doz kortikosteroid, hidroksiklorokin, metotreksat ve siklosporin-A tedavileri ile eklem bulguları düzelirken lökopeni sebat etti. Haftada üç gün olmak üzere 30 MÜ/gün dozunda "siklik" G-CSF tedavisi başlanan ve lökopenisi düzelen hastaya splenektomi uygulandı. Splenektomi sonrası ikinci ayda lökopeninin nüksetmesi üzerine, yeniden siklik G-CSF uygulamasına geçildi. Hasta halen takibinin 8. ayında remisyonda izlenmektedir. FS'de G-CSF tedavisi gerek remisyon indüksiyonu gerekse sürdürme tedavisinde etkili ve güvenilir bir tedavi seçeneği olarak görünmektedir.

🔖

Cite This Article

GÜL, A., KAMALI, S., KASAPOĞLU, E., ÇAĞATAY, Y., MUTLU, A. Ş., ÖCAL, L., KONİÇE, M., İNANÇ, M. (2022). Felty's syndrome: Sucesful remission induction and meintenance therapy with granulocyte macrophage colony stimulating factor. İstanbul Üniversitesi İstanbul Tıp Fakültesi Mecmuası, Cilt: 65 - Sayı: 4, 279–282. https://ajindex.com/articles/553733

References (13)

  1. Turesson C, O’Fallon WM, Crowson CS, Gabriel SE, Matteson EL. Occurrence of extraarticuler disease manifestations is associated with excess mortality in a community based cohort of patients with rheumatoid arthritis. J Rheumatol; 29:62 (2002)
  2. Wollheim FA. Rheumatoid arthritis – the clinical picture. In: Maddison PJ, Isenberg DA, Woo P, Glass DN, eds. Oxford Textbook of Rheumatology 2nd ed. New York: Oxford University Press,:1352-1365 (1998)
  3. Breedveld FC, Fibbe WE, Cats A. Neutropenia and infections in Felty’s syndrome. Br J Rheumatol; 27:19 (1988)
  4. Hellmich B, Csernok E, de Haas M, von dem Borne A, Schatz H, Gross WL, Schnabel A. Low FcgReceptor III and high granulocyte colony-stimulating factor serum levels correlate with the risk of infection in neutropenia due to Felty’s syndrome or systemic lupus erythematosus. Am J Med; 113:134 (2002)
  5. Sibley JT, Haga M, Visram DA, Mitchell DM. The clinical course of Felty’s syndrome compared to matched controls. J Rheumatol; 18:1163 (1991)
  6. Fiechtner JJ, Miller DR, Starkebaum G. Reversal of neutropenia with methotrexate treatment in patients with Felty’s syndrome. Correlation of response with neutrophil-reactive IgG. Arthritis Rheum; 32:194 (1989)
  7. Wassenberg S, Herborn G, Rau R. Methotrexate treatment in Felty’s syndrome. Med Hypotheses; 50:415 (1998)
  8. Talip F, Walker N, Khan W, Zimmermann B. Treatment of Felty’s syndrome with leflunomide. J Rheumatol; 28:868 (2001)
  9. Canvin JM, Dalal BI, Baragar F, Johnston JB. Cyclosporine for the treatment of granulocytopenia in Felty’s syndrome. Am J Hematol; 36:219 (1991)
  10. Dillon AM, Luthra HS, Conn DL. Parenteral gold therapy in the Felty’s syndrome. Experience with 20 patients. Medicine 65:107 (1986)
  11. Graham KE, Coodley GO. A prolonged use of granulocyte stimulating factor in Felty’s syndrome. J Rheumatol; 22:174 (1995)
  12. Stanworth SJ, Bhavnani M, Chattopadhya C, Miller H, Swinson DR. Treatment of Felty’s syndrome with the haemopoietic growth factor granulocyte colony-stimulating factor (G-CSF). QJM;91:49 (1998)
  13. Krishnaswany G, odem C, Chi DS, Kalbfleisch J, Baker N, Smith JK. Resolution of neutropenia of Felty’s stndrome by longterm administration of recombinant granulocyte colony stimulating factor. J Rheumatol 1996;23(4):763-5 14. Hellmich B, Schnabel A, Gross WL. Treatment of severe neutropenia due to Felty’s syndrome or systemic lupus erythematosus with granulocyte colony-stimulating factor. Semin Arthritis Rheum;29:82 (1999)